Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
TLDR
In the EU, the highest age-standardised incidence rates for oesophageal cancer are in the Netherlands for men and the UK for women, and variation between countries is high and may reflect different prevalence of risk factors, use of screening and diagnostic methods.About:
This article is published in Annals of Oncology.The article was published on 2013-10-01 and is currently open access. It has received 810 citations till now. The article focuses on the topics: European union & Cancer.read more
Citations
More filters
Journal ArticleDOI
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato,Byoung Chul Cho,Masanobu Takahashi,Morihito Okada,Chen Yuan Lin,Keisho Chin,Shigenori Kadowaki,Myung-Ju Ahn,Yasuo Hamamoto,Yuichiro Doki,Chueh Chuan Yen,Yutaro Kubota,Sung Bae Kim,Chih-Hung Hsu,Eva Holtved,Ioannis Xynos,Mamoru Kodani,Yuko Kitagawa +17 more
TL;DR: Overall survival was significantly improved in the nivolumab group compared with the chemotherapy group, and a favourable safety profile compared with chemotherapy in previously treated advanced oesophageal squamous cell carcinoma patients.
Journal ArticleDOI
Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.
Hong Yang,Hui Liu,Yuping Chen,Chengchu Zhu,Wentao Fang,Zhentao Yu,Weimin Mao,Jiaqing Xiang,Yongtao Han,Zhijian Chen,Haihua Yang,Jiaming Wang,Qingsong Pang,Xiao Zheng,Huanjun Yang,Tao Li,Florian Lordick,Xavier B. D’Journo,Robert J. Cerfolio,Robert J. Korst,Nuria M. Novoa,Scott J. Swanson,Alessandro Brunelli,Mahmoud Ismail,Hiran C. Fernando,Xu Zhang,Qun Li,Geng Wang,Baofu Chen,Teng Mao,Min Kong,Xufeng Guo,Ting Lin,Mengzhong Liu,Jianhua Fu +34 more
TL;DR: This trial shows that NCRT plus surgery improves survival over surgery alone among patients with locally advanced ESCC, with acceptable and manageable adverse events.
Journal ArticleDOI
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial
Thierry Conroy,Marie-Pierre Galais,Jean-Luc Raoul,Olivier Bouché,Sophie Gourgou-Bourgade,Jean-Yves Douillard,Pierre-Luc Etienne,Valérie Boige,Isabelle Martel-Lafay,Pierre Michel,Carmen Llacer-Moscardo,Eric Francois,Gilles Créhange,Meher Ben Abdelghani,Beata Juzyna,Laurent Bedenne,Antoine Adenis +16 more
TL;DR: The PRODIGE5/ACCORD17 trial aimed to assess the efficacy and safety of the FOLFOX treatment regimen versus fluorouracil and cisplatin as part of chemoradiotherapy in patients with localised oesophageal cancer.
Journal ArticleDOI
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
TL;DR: In this paper , the authors compared first-line chemotherapy for advanced esophageal squamous-cell carcinoma with the monoclonal antibody nivolumab plus chemotherapy.
Journal ArticleDOI
Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated January 2017.
Jean-Marc Dumonceau,Pierre Henri Deprez,Christian Jenssen,Julio Iglesias-Garcia,Alberto Larghi,Geoffroy Vanbiervliet,Guruprasad P. Aithal,Paolo Giorgio Arcidiacono,Pedro Bastos,Silvia Carrara,László Czakó,Gloria Fernández-Esparrach,Paul Fockens,Angels Ginès,Roald Flesland Havre,Cesare Hassan,Peter Vilmann,Jeanin E. van Hooft,Marcin Polkowski +18 more
TL;DR: ESGE suggests performing EUS-guided sampling for the assessment of regional lymph nodes in T1 (and, depending on local treatment policy, T2) adenocarcinoma and of lesions suspicious for metastasis such as distant LNs, left liver lobe lesions, and suspected peritoneal carcinomatosis.
References
More filters
Journal ArticleDOI
Volume-outcome relationship in surgery for esophageal malignancy: systematic review and meta-analysis 2000-2011.
TL;DR: This meta-analysis does suggest a benefit in the centralization of esophageal cancer surgery to high-volume institutions with respect to mortality and the outcomes of this study are of interest to patients, healthcare providers and payers.
Journal ArticleDOI
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
Susan J Dutton,D. R. Ferry,Jane M Blazeby,Jane M Blazeby,Haider Abbas,Asa Dahle-Smith,Wasat Mansoor,Joyce Thompson,Mark Harrison,Anirban Chatterjee,Stephen Falk,Angel Garcia-Alonso,D. Fyfe,Richard A Hubner,Tina Gamble,Lynnda Peachey,Mina Davoudianfar,Sarah Pearson,Patrick Julier,Janusz Jankowski,Rachel Kerr,Russell D. Petty +21 more
TL;DR: The use of gefitinib as a second-line treatment in oesophageal cancer in unselected patients does not improve overall survival, but has palliative benefits in a subgroup of patients with short life expectancy.
Journal ArticleDOI
Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers.
Oliver Pech,Elfriede Bollschweiler,Hendrik Manner,Jessica M. Leers,Christian Ell,Arnulf H. Hölscher +5 more
TL;DR: For patients with mucosal BC, both surgery and ER are effective treatment modalities, however, the recurrence rate is higher in patients treated with ER, so that thorough follow-up procedures are mandatory.
Journal ArticleDOI
Oesophagogastric junction adenocarcinoma: which therapeutic approach?
TL;DR: Findings from the latest randomised trials and meta-analyses are reviewed, and guidelines regarding endoscopic, surgical, and perioperative treatments regarding resectable OGJA are proposed.
Journal ArticleDOI
Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer
TL;DR: This meta‐analysis sought to clarify the benefits of neoadjuvant and definitive treatment for OSCC.
Related Papers (5)
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
Joel Shapiro,J. Jan B. van Lanschot,Maarten C.C.M. Hulshof,Pieter van Hagen,Mark I. van Berge Henegouwen,Bas P. L. Wijnhoven,Hanneke W. M. van Laarhoven,Grard A. P. Nieuwenhuijzen,Geke A. P. Hospers,Johannes J. Bonenkamp,Miguel A. Cuesta,Reinoud J. B. Blaisse,Olivier R. Busch,Fiebo J. W. ten Kate,Geert-Jan Creemers,Cornelis J. A. Punt,John T. M. Plukker,Henk M.W. Verheul,Ernst Jan Spillenaar Bilgen,Herman van Dekken,Maurice J.C. van der Sangen,Tom Rozema,Katharina Biermann,Jannet C. Beukema,Anna H.M. Piet,Caroline M. van Rij,Janny G. Reinders,Hugo W. Tilanus,Ewout W. Steyerberg,Ate van der Gaast +29 more